Robert Dillman

Company: AiVita Biomedical

Job title: Chief Medical Officer

Seminars:

Leveraging Regulatory Momentum to Accelerate the Path to Approval for Personalized Cancer Vaccines 5:00 pm

• Strategically pursuing designations like Breakthrough Therapy or ISTs to validate early clinical signals, gain FDA partnership, and build external confidence in your platform’s viability • Using regulatory milestones to strengthen investor narratives by showcasing derisked development timelines, alignment with FDA expectations, and faster routes to market • Designing early trials with regulatory engagement in…Read more

day: Conference Day Two

Achieving Sub-3-Week PCV Manufacturing: Leveraging Biopsy Timing & Dendritic Cell Delivery to Eliminate Bottlenecks & Improve Access 11:30 am

• Coordinating tumor biopsy with standard-of-care procedures to streamline sample collection and preserve cell viability • Using biologically driven antigen selection and dendritic cell delivery to bypass lengthy genomic prediction and adjuvant formulation • Reducing turnaround time to under 3 weeks and costs below $10K to improve patient accessRead more

day: Pre-Conference Manufacturing Focus Day